TXNRD1是肝细胞癌患者的不良预后因素。
TXNRD1 Is an Unfavorable Prognostic Factor for Patients with Hepatocellular Carcinoma.
作者信息
Fu Binsheng, Meng Wei, Zeng Xiancheng, Zhao Hui, Liu Wei, Zhang Tong
机构信息
Department of Hepatic Surgery and Liver Transplantation Center of the Third Affiliated Hospital, Organ Transplantation Institute of Sun Yat-sen University, Organ Transplantation Research Center of Guangdong Province, Guangzhou 510630, China.
Department of General Surgery, The Second People's Hospital of Guangdong Province, Guangzhou 510317, China.
出版信息
Biomed Res Int. 2017;2017:4698167. doi: 10.1155/2017/4698167. Epub 2017 Apr 27.
Thioredoxin reductase 1 (TXNRD1) which is a selenocysteine-containing protein is overexpressed in many malignancies. Its role in the hepatocellular carcinoma (HCC) prognosis has not been investigated. In this study, we investigated whether TXNRD1 functions as an independent prognostic factor for HCC patients. We found TXNRD1 was overexpressed in HCC tissues and cells, immunohistochemical analysis suggested TXNRD1 was elevated in 57 of 120 (47.5%) clinical samples, and its level was increased with the increasing clinical stage. In addition, TXNRD1 expression was positively correlated with clinical stage ( = 3.5 - 5), N classification ( = 4.4 - 4), and M classification ( = 0.037) of HCC patients. Kaplan-Meier analysis revealed that patients with high TXNRD1 expression had significantly shorter survival time than patients with low TXNRD1 expression. Multivariate analysis found TXNRD1 was an independent prognostic factor for HCC patients. In conclusion, our data suggested that TXNRD1 was a biomarker for the prognosis of patients with HCC.
硫氧还蛋白还原酶1（TXNRD1）是一种含硒代半胱氨酸的蛋白质，在许多恶性肿瘤中均有过表达。其在肝细胞癌（HCC）预后中的作用尚未得到研究。在本研究中，我们调查了TXNRD1是否作为HCC患者的独立预后因素发挥作用。我们发现TXNRD1在HCC组织和细胞中过表达，免疫组化分析表明，在120例临床样本中有57例（47.5%）TXNRD1升高，且其水平随临床分期的增加而升高。此外，TXNRD1表达与HCC患者的临床分期（=3.5 - 5）、N分级（=4.4 - 4）和M分级（=0.037）呈正相关。Kaplan-Meier分析显示，TXNRD1高表达患者的生存时间明显短于TXNRD1低表达患者。多因素分析发现TXNRD1是HCC患者的独立预后因素。总之，我们的数据表明TXNRD1是HCC患者预后的一个生物标志物。
Zotero 插件